A Billionaire Investor Just Said "Some of This Peptide Stuff Has Shown an Effect" on Age Reversal. Here's Exactly What He Means for Australians Right Now

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

On a recent episode of Modern Wisdom, All-In podcast co-host and venture capitalist David Friedberg told host Chris Williamson that age reversal clinical trials are running now, the technology works in animals, and — crucially — that "some of this peptide stuff that people are crazy about has shown that it has an effect" as a bridge strategy while the big therapies reach market. This article explains the science Friedberg described, why his peptide comment is more significant than it sounds, and exactly which compounds Australians can access today through legal AHPRA-registered pathways.

Watch the full clip on Modern Wisdom →

Who is David Friedberg — and why does this matter?

David Friedberg is a founding partner of the All-In Fund, former Google executive, and co-host of the All-In Podcast alongside Chamath Palihapitiya, Jason Calacanis, and David Sacks. He is not a wellness influencer. He is a scientist-investor who has put serious capital behind biotech and longevity ventures. When Friedberg describes a technology as one of the most exciting things he has ever seen, the scientific and financial communities pay attention.

Chris Williamson hosts Modern Wisdom, one of the most-listened podcasts globally for health optimisation and applied science. The conversation — episode #1084, "Everything You Know Is About to Collapse" — covers AI, energy, and longevity. The age reversal section is approximately ten minutes and contains some of the clearest layperson explanations of epigenetic reprogramming you will find outside a university lecture.

Your DNA is not the problem. Your epigenome is — and that changes everything

Friedberg's explanation of the science is worth working through carefully, because the mechanism determines the solution.

Every cell in your body carries identical DNA. Your eye cell, heart cell, skin cell, and brain cell all have the same genetic code. What makes them different is which genes are switched on and which are switched off — molecular markers that sit on top of the DNA. This layer is called the epigenome.

Friedberg used a vivid analogy. Imagine a cell is the size of Manhattan — 500-storey buildings, 10 billion proteins running between them, never sleeping, always working, building and breaking things together. "That's one second in one cell. That's how complex this is."

The epigenome is the software running on that city. It tells each protein whether to clock in or stay home. Epigenetic markers are the ones and zeros — on or off — that determine whether you have an eye cell or a heart cell or a skin cell.

Here is the mechanism of ageing: your DNA gets damaged constantly. Radiation, sunlight, alcohol, processed food — these all cause DNA breaks. Your cells are extraordinarily good at repairing these breaks. But every repair event carries a small risk of nudging those epigenetic markers — those ones and zeros — slightly out of position. Over decades, this accumulates. Wrong genes get turned on. Right genes get turned off. The eye cell starts behaving like a slightly older eye cell. The heart cell loses a fraction of its capacity. The skin cell produces less collagen.

Friedberg's framing: "It looks like the root of all disease may be aging, and aging is a disease — rooted in the fact that these little epigenetic molecules move around to the wrong place."

This reframing is profound. Ageing is not hardware failure. The DNA is largely intact. Ageing is software corruption — and software can be rebooted.

What Yamanaka factors actually do — the Nobel Prize discovery that changes the timeline

In 2006, Japanese scientist Shinya Yamanaka discovered that four specific proteins — now called Yamanaka factors — could take an adult cell and reset all its epigenetic markers, reverting it to a stem cell capable of becoming any other cell type. He won the Nobel Prize in 2012.

The problem with full reset is obvious. If your heart cell loses its identity and becomes a stem cell, it can no longer pump blood. That is cancer territory, not rejuvenation.

The breakthrough came a decade later. Researchers published papers showing that applying a smaller dose of the Yamanaka factors — partial reprogramming — does not erase cellular identity. It moves the corrupted epigenetic markers back to where they were in a young cell. The eye cell stays an eye cell. But it now behaves like the eye cell it was twenty years ago.

Friedberg described the animal results: "They did this in mice and they made the mice the equivalent of living 250-plus years old. They put it in monkeys — the wrinkles went away. And they've applied it to retinal cells in the eye and reversed blindness."

These are not anecdotal reports. Sinclair's lab at Harvard has published peer-reviewed research on epigenetic reprogramming reversing blindness in mice. The Salk Institute published lifespan extension data in 2016. Multiple independent labs have replicated the cellular age reversal findings.

The clinical trials running right now — and Friedberg's timeline

When Chris Williamson asked how far off age reversal was — "One decade? Five decades?" — Friedberg's answer was immediate: "Way less than that. We are in clinical trials now on several of these cocktails."

The companies Friedberg named:

David Sinclair's company is in clinical trials. Sinclair's Harvard lab published research in 2023 showing that six chemical cocktails could restore youthful gene expression in human cells in less than a week without disrupting cellular identity.

Altos Labs — which Friedberg described as "one of the most funded startups in history that no one talks about" — has raised close to $10 billion to pursue partial cellular reprogramming at scale. Jeff Bezos is among its backers.

Dozens of other companies are pursuing variations of the approach — some with the original Yamanaka proteins, others with small molecules that mimic the effect without gene therapy.

Friedberg's timeline: "Over the next 10 to 20 years, more of this starts to proliferate."

He acknowledged the gap between animal and human results — "there's always a risk in going from animals to humans" — but noted that human cell experiments in vitro are already showing the expected effects.

Find a ProtocolHub longevity clinic that tracks your biological age →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

Friedberg's exact words on peptides — the bridge strategy he named

This is the section most relevant to ProtocolHub readers — and it comes directly from the transcript, word for word.

After Williamson raised longevity escape velocity and the idea of "holding on" until age reversal therapies arrive, Friedberg said:

"The number one thing you can do to fix your epigenome, which you can do without taking these drugs, is exercise."

He acknowledged fasting has an effect. Then — unprompted — he said this:

"And then there's other things that you can start to take. Some of this peptide stuff that people are crazy about has shown that it has an effect. I don't want to be prescriptive on these things. But there's a lot of ways that you can start to kind of edge your way before all the big clinical stuff is done and the big products come out to market."

A billionaire biotech investor who just spent ten minutes explaining the most credible age reversal science in the world — spontaneously, on a mainstream podcast — naming peptides as a valid bridge strategy before the clinical therapies arrive.

This is not a celebrity endorsing a supplement. This is someone who understands the mechanistic science saying: some of these compounds are working on the epigenome right now, in ways that are consistent with what the Yamanaka research is targeting.

He was careful not to be prescriptive. ProtocolHub will be.

The longevity escape velocity argument — and why Williamson's framing is the most important thing in this conversation

Peter Diamandis coined the concept of longevity escape velocity: if medical science can extend healthy lifespan by more than one year for every year you live, you have crossed a threshold where ageing ceases to be a fixed deadline. Williamson applied this directly: "Now is not the time to f--- it."

In every previous era, the marginal health decision was worth five to ten years of additional healthy life. Worth doing — but the upside was bounded.

If age reversal therapies work as the animal data suggests, and if they arrive in 10–20 years, the upside of arriving at that window in good biological condition is categorically different. Friedberg's framing: "You're like — hey, keep it together."

The person who arrives at 58 with a biological age of 45, strong lean mass, optimised hormonal function, and maintained NAD+ levels is a fundamentally different candidate for these therapies than someone who arrives with a biological age of 70, metabolic disease, and depleted cellular repair capacity.

This is the longevity argument for peptide protocols that has never been made this directly before: you are not optimising for today's standard of care. You are optimising for therapies that will exist in 10–20 years and whose efficacy will depend partly on your biological state when they arrive.

The Australian bridge protocol — what to do right now

Friedberg said "some of this peptide stuff." Here is the specific list of compounds available in Australia through legal AHPRA-registered pathways that most directly address the epigenetic and cellular mechanisms he described.

NMN — the NAD+ restoration compound

NMN is a direct precursor to NAD+, required for the SIRT1 and SIRT3 pathways that regulate epigenetic maintenance and DNA repair. The worker proteins Friedberg described — the ones that fix DNA breaks — require adequate NAD+ to function. NAD+ levels decline approximately 50% between age 20 and 60. Restoring them supports the same cellular repair machinery that Yamanaka factor research is targeting from the top down.

Andrew Huberman takes 1–2 g/day. Bryan Johnson takes 500 mg/day as part of Blueprint.

Australian access: TGA-approved, no prescription required. iHerb Australia, Chemist Warehouse, specialist supplement retailers. Cost: $50–$80 AUD/month.

Epithalon — the most mechanistically relevant compound on this list

Epithalon is a synthetic tetrapeptide that directly activates telomerase — the enzyme that repairs and extends telomeres. Short telomeres are among the most consistent biomarkers of epigenetic age. Epithalon also directly stimulates epigenetic regulatory activity in the pineal gland and has demonstrated effects on gene expression patterns consistent with cellular rejuvenation.

Of all compounds currently available in Australia, Epithalon is the one with the most direct mechanistic connection to the epigenetic ageing pathway Friedberg described. It is not a Yamanaka factor. But it works on the same underlying problem — epigenetic drift — through an adjacent pathway.

Australian access: Schedule 4 research-use. Requires AHPRA-registered prescription and medical supervision. Annual course (5–10 mg/day for 10–20 days, 1–2 times per year). Cost: $150–$280 AUD per course (~$25–$47/month amortised).

GHK-Cu — tissue remodelling and cellular regeneration

GHK-Cu is a naturally occurring copper tripeptide that declines significantly with age. It promotes collagen synthesis, stem cell proliferation, anti-inflammatory activity, and antioxidant enzyme expression. Its mechanism — promoting the regeneration of cellular structures — is adjacent to the tissue-level rejuvenation effects being targeted by partial reprogramming research.

Bryan Johnson uses it topically in his Blueprint serum. Injectable GHK-Cu achieves systemic tissue remodelling beyond topical application.

Australian access: Compounding-only, Schedule 4. AHPRA-registered prescription and licensed compounding pharmacy. Cost: $120–$200 AUD/month.

Ipamorelin + CJC-1295 — GH axis maintenance for cellular repair

Ipamorelin + CJC-1295 supports GH pulse amplitude, which declines from the mid-30s onward. Growth hormone drives tissue repair, lean mass maintenance, and cellular renewal during sleep. Peter Attia's longevity framework identifies lean mass maintenance as one of the strongest predictors of all-cause mortality — the GH secretagogue layer supports this system across the ageing process.

Australian access: Schedule 4. AHPRA-registered prescription and licensed compounding pharmacy. Cost: $150–$250 AUD/month.

The full Australian bridging protocol — cost summary

Compound	Mechanism	Monthly cost (AUD)	Prescription?
NMN 500 mg–1 g/day	NAD+ and epigenetic repair support	$50–$80	No
Epithalon (amortised)	Telomerase activation, epigenetic maintenance	$25–$47	Yes
GHK-Cu injectable	Tissue remodelling, cellular regeneration	$120–$200	Yes
Ipamorelin + CJC-1295	GH axis, lean mass, sleep-phase repair	$150–$250	Yes
OTC only (NMN)		$50–$80/month	—
Full bridging stack		$345–$577/month	—

The full ProtocolHub implementation of this framework is available as two protocols: the Blueprint Longevity Protocol, which follows Bryan Johnson's compound-first approach, and the Outlive Longevity Protocol, which follows Peter Attia's biomarker-first approach — baseline blood work first, then the compounds that the markers justify.

For Australians who want a prescriber that takes the biomarker-led approach Friedberg described — measuring the epigenome and titrating interventions based on individual data — Thrive Rx's blood-panel-included intake model is the closest on ProtocolHub to what this science actually demands.

The number one thing Friedberg said you can do right now

Before any compound, before any peptide, Friedberg named exercise as the primary epigenome intervention available without clinical access.

"Exercise releases molecules that in many cells in your body will go in and start to address the epigenome and make you more youthful."

This is consistent with the published research. Resistance training and aerobic exercise both influence DNA methylation patterns — the same markers that the Yamanaka factor research is targeting pharmacologically. Exercise is the free, accessible, no-prescription version of epigenetic maintenance that compounds over decades.

Fasting also has an effect, Williamson noted. Friedberg agreed.

The bridge protocol is: exercise first, then fasting and sleep, then the compounds. The peptides Friedberg referenced work on the margin of a foundation that has already been established. They do not replace the foundation.

---

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice.

What to read next

• The Blueprint Longevity Protocol — the most comprehensive Australian longevity stack based on Bryan Johnson's framework
• The Outlive Longevity Protocol — Peter Attia's biomarker-first approach, translated for Australia
• Epithalon peptide profile — the telomere and epigenetic maintenance compound
• NMN peptide profile — NAD+ restoration and its role in cellular repair
• GHK-Cu peptide profile — tissue remodelling and cellular regeneration
• Longevity protocol guide — Australia — the complete reference
• Compare Australian longevity clinics